Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03258281 · ClinicalTrials.gov registry record · Phase 4
Effects of Evolocumab on Platelet Reactivity in Patients With Diabetes Mellitus
A Phase 4 study, sponsored by Inova Health Care Services.
- Terminated
- Registry status
- Phase 4
- Development phase
- 4
- Enrollment target
NCT03258281 is a Phase 4 study that was terminated before completion, run by Inova Health Care Services. The registered enrollment target is 4 participants.
The verdict
NCT03258281, a Phase 4 study, was terminated before completion, sponsored by Inova Health Care Services.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 4 participants
- Enrollment target
Study Summary
Prospective, single center, double-blind, randomized pharmacodynamic experimental study. The study will enroll 150 subjects with ASCVD on optimal statin therapy as per physician and Diabetes Mellitus (DM) undergoing elective Percutaneous Coronary Intervention (PCI). Eligible patients will be randomized for 30 day treatment to either 1) evolocumab 420 mg ; or 2) placebo.
Interventions
- DRUG Placebo
- DRUG Evolocumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2018-05-01 |
| Est. Completion | 2019-10-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03258281
The ClinicalTrials.gov registry entry for NCT03258281 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Inova Health Care Services, which has 75 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03258281 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03258281 about?
NCT03258281 is a clinical study titled "Effects of Evolocumab on Platelet Reactivity in Patients With Diabetes Mellitus". Prospective, single center, double-blind, randomized pharmacodynamic experimental study. The study will enroll 150 subjects with ASCVD on optimal statin therapy as per physician and Diabetes Mellitus (DM) undergoing elective Percutaneous Coronary Intervention (PCI). Eligible patients will be randomi...
What is the current status of trial NCT03258281?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 4 participants. The study started on 2018-05-01. Estimated completion is 2019-10-01.
What interventions are being tested in trial NCT03258281?
The interventions under investigation include: Placebo (DRUG), Evolocumab (DRUG).
Who is sponsoring clinical trial NCT03258281?
This trial is sponsored by Inova Health Care Services, which has 75 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.